Navigation Links
West to Host 2008 Fourth Quarter Conference Call
Date:2/12/2009

LIONVILLE, Pa., Feb. 12 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will release 2008 fourth quarter financial results before the market opens on Thursday, February 19, 2009 and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial (888)790-3758 or (210)839-8398. The passcode is WST.

A live broadcast of the conference call will be available at the Company's web site, www.westpharma.com, in the "Investor" section. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.

An online archive of the broadcast will be available at the site two hours after the live call and will be available through Thursday, March 5, 2009, by dialing 800-873-2026 or 402-220-5359 and entering conference ID# 5220719.

About West

West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.

    Contacts:                            Investors and Financial Media:
    West                                 FD
    Michael A. Anderson                  Evan Smith / 
'/>"/>
SOURCE West Pharmaceutical Services, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2008 Financial Results
2. Cambrex Reports Fourth Quarter and Full Year 2008 Results
3. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
4. Symmetry Medical to Report Fourth Quarter and Full Year 2008 Financial Results on February 24, 2009
5. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 18, 2009 to Discuss Fourth Quarter 2008 Results
6. Kresge Foundation Meets Economic Downturn Head on, Awarding a Record $63.6 Million in Grants in Fourth Quarter 2008
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. Triple-S Management Corporation Announces Delay in Reporting Fourth-Quarter And Year-End Results
9. Hanger Orthopedic Group, Inc. Reports $0.26 Pro Forma EPS on 8.6% Sales Growth for the Fourth Quarter 2008
10. Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008
11. LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Hemodialysis equipment is the most widely used ... acute or chronic renal failure. , The Chinese hemodialysis ... European, American and Japanese enterprises. In 2013, the import ... growing demand for hemodialysis equipment in China, its import ... in 2009-2013. Germany, Sweden and Japan as the main ...
(Date:7/23/2014)... month of July, LunaDress, a well-known wedding dress manufacturer and ... hosting a couple of promotions on its website. Recently, the ... wedding dresses for the UK market . The fresh range ... are now offered with huge discounts, from 20 to 70 ... suppliers, LunaDress is always making full efforts to offer classy ...
(Date:7/23/2014)... 23, 2014 World Gardens Café, the ... healthy gourmet cuisine, received rave reviews last week when ... Mixer. Mixer attendees were amazed that healthy food could ... World Gardens Café, the premier provider of delicious and ... booth at Dave Linden’s LA’s Largest Mixer. Attendees who ...
(Date:7/23/2014)... 2014 Sanuvox has produced a ... of the company’s latest system designed for hospital ... System uses a primary and secondary unit to ... ‘C’ energy controlling (6 log reduction) drug-resistant microorganisms ... than 10 minutes in a standard patient hospital ...
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative costs ... up with alternative means to becoming self-sustaining. Industry ... accomplish this in the July 17 issue of ... , “We never expected the operating budgets would ... an attorney at the law firm Venable LLP ...
Breaking Medicine News(10 mins):Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 2Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 3Health News:China Hemodialysis Equipment Market (Import & Export) Report 2013-2016 Now Available at ChinaMarketResearchReports.com 4Health News:LunaDress Continues To Enrich Product Line By Offering Short Summer Beach Wedding Dresses 2Health News:Healthy Food Gets Rave Reviews at LA’s Largest Mixer 2Health News:Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3
... from the University of North Carolina at Chapel Hill suggests that ... morning or later in the afternoon can influence the onset ... exposure to UV radiation in the morning increased the risk of ... Although mice and humans both reside on a 24-hour day, the ...
... Rockville, MD -- Physical activity may be what the ... developing glaucoma. According to a recently published scientific paper, ... long-term beneficial impact on low ocular perfusion pressure (OPP), ... the Investigative Ophthalmology & Visual Science journal ...
... LANSING, Mich. -- Despite the fact mental health problems ... combined, about two-thirds of mental health patients are cared ... Additionally, even larger numbers of other patients regularly ... A new five-year, $1 million grant allows Michigan State ...
... related macular degeneration (AMD) is the leading cause of ... identified several relatively common genetic variants which together predict ... number of persons without the disease also have these ... able to clearly show a specific rare mutation called ...
... study published today in the journal Nature Genetics ... Lieb, PhD, present experiments supporting a longstanding hypothesis that ... of the X chromosome. The finding provides clarity to ... with more information to interpret experiments involving genetic measurements ...
... FESC, from the University of Padua, Italy, explains, "To ... from all the different imaging modalities, not just Echo. ... is that we want to become more patient oriented, ... the most appropriate technology to address individual clinical questions." ...
Cached Medicine News:Health News:Morning UV exposure may be less damaging to the skin 2Health News:Physical fitness could have a positive effect on eye health 2Health News:Residency program focuses on overlooked mental health needs 2Health News:Researchers ID genetic mutation associated with high risk of age-related macular degeneration 2Health News:Study confirms males and females have at least 1 thing in common: Upregulating X 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 2Health News:Congress alert: EUROECHO and Other Imaging Modalities: New patient emphasis 3
(Date:7/22/2014)... Elekta (NSE:EKTAb) and Royal Philips ... Foundation Trust ( Manchester, UK ), a ... is to develop the clinical value of an integrated ... a system would, in principle, improve the practice of ... "The Christie was an essential participant in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... ALL Study Group Presented Data at the 14th Congress ... in Patients with Minimal Residual Disease , , ... MITI ), a biopharmaceutical company developing novel, proprietary antibodies ... announced that the German Multicenter ALL Study Group (GMALL) ...
... 2 data sets to be released-- , ... clinical trials in patients with blepharospasm and cervical dystonia -- ... -- were presented at the Movement Disorder Society (MDS) 13th ... by Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 2Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 3Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 5Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: